Results 301 to 310 of about 112,794 (342)

[Cyclooxygenase inhibitors].

Presse medicale (Paris, France : 1983), 2001
DISTINCT EFFECTS: Since the discovery of the two isoforms of COX, the therapeutic effects of nonsteroidal antiinflammatory drugs (NSAID) can be distinguished from their adverse effects linked to the inhibition of the constitutional form via selective inhibition of the inducible form.
P, Eschwège, V, de Ledinghen, T, Camilli, S, Kulkarni, G, Dalbagni, S, Droupy, A, Jardin, G, Benoît, B B, Weksler   +8 more
openaire   +1 more source

Cyclooxygenase-2 selective inhibitors

Drugs of Today, 1999
The identification of two cyclooxygenase (COX) enzymes has been a tremendous advance in understanding the role of prostaglandins in inflammation and the actions of nonsteroidal antiinflammatory drugs (NSAIDs). COX-1 activity appears to be related to "constitutive" or "housekeeping" functions in the gastric mucosa, kidney and platelets.
openaire   +2 more sources

Rofecoxib: A specific cyclooxygenase inhibitor

Drugs of Today, 2000
Rofecoxib is a new specific cyclooxygenase-2 inhibitor. The efficacy of rofecoxib has been established in the treatment of osteoarthritis, rheumatoid arthritis and acute pain. Rofecoxib has been approved in the United States for the treatment of osteoarthritis and acute pain. Endoscopically proven gastrointestinal ulceration is much less with rofecoxib
openaire   +2 more sources

Cyclooxygenase-2 Inhibitors

Current Pharmaceutical Design, 1995
Prostaglandins are synthesized by the enzyme cyclooxygenase (COX), which is the target for nonsteroidal anti-inflammatory drugs (NSAIDs). Recently a second form of COX was discovered (COX-2) that is induced by inflammatory stimuli. The identification of an inducible form of COX led to the hypothesis that COX-2 is responsible for inflammatory ...
David B. Reitz, Peter C. Isakson
openaire   +1 more source

The Coxibs, Selective Inhibitors of Cyclooxygenase-2

New England Journal of Medicine, 2001
Nonsteroidal antiinflammatory drugs (NSAIDs) are widely used to treat arthritis, menstrual pain, and headache. Although they are effective, their long-term use is limited by gastrointestinal effects such as dyspepsia and abdominal pain and, less often, gastric or duodenal perforation or bleeding.
FitzGerald, Garret A., Patrono, Carlo
openaire   +3 more sources

[Pharmacology and classification of cyclooxygenase inhibitors].

Gastroenterologie clinique et biologique, 2004
The discovery of at least two cyclooxygenase (COX) isoenzymes had two major consequences: i) to give a new impetus to the research on lipid metabolism, giving rise to the crystallization of these peculiar membrane enzymes, the characterization of their active sites and their gene regulation, and the identification of new metabolic pathways; ii) the ...
Jouzeau, Jean-Yves, Daouphars, Mikaël, Benani, Alexandre, Netter, Patrick   +3 more
openaire   +2 more sources

Cyclooxygenase-2 Inhibitor Celecoxib:

Southern Medical Journal, 2000
Gastrointestinal side effects from nonsteroidal anti-inflammatory drugs (NSAIDs) result mainly from inhibition of the enzyme cyclooxygenase (COX)-1; it is responsible for the synthesis of prostaglandin E2, which leads to increased mucosal blood flow, increased bicarbonate secretion, and mucus production, thus protecting the gastrointestinal mucosa.
J D, Linder, K E, Mönkemüller, J V, Davis, C M, Wilcox   +3 more
openaire   +2 more sources

Clinical experience with cyclooxygenase-2 inhibitors

Inflammation Research, 1999
Increasing amounts of experimental and clinical data support the role of selective cyclooxygenase (COX)-2 inhibition in anti-inflammatory processes and the role of COX-1 inhibition in increasing the frequency of side effects. This article reviews the regulation of COX-2 in inflammatory processes based on in vitro and in vivo work.
J, van Ryn, M, Pairet
openaire   +2 more sources

Thalidomide and its analogues as cyclooxygenase inhibitors

Bioorganic & Medicinal Chemistry Letters, 2002
Thalidomide showed cyclooxygenase (COX)-1/2 inhibitory activity with a potency comparable to that of aspirin. Structural development studies of thalidomide resulted in potent COX-1/2 inhibitors, and COX-1-selective and COX-2-selective inhibitors.
Tomomi, Noguchi, Rumiko, Shimazawa, Kazuo, Nagasawa, Yuichi, Hashimoto   +3 more
openaire   +2 more sources

Cyclooxygenase inhibitors: drugs for cancer prevention

Current Opinion in Pharmacology, 2003
Evidence that chronic intake of non-steroidal anti-inflammatory drugs, especially aspirin, prevents cancer development continues to accumulate. The data are particularly convincing for colorectal cancer; however, because of well-known side effects, they cannot routinely be recommended for this purpose.
Steven J, Shiff, Punitha, Shivaprasad, Diana L, Santini   +2 more
openaire   +2 more sources